Matters
- Expanded foundational patent portfolio for startup client with new platform for producing engineered Natural Killer (NK) cells, and defended patent due diligence leading to the client’s successful acquisition by an established, pre-clinical cell therapy company and shortly later the purchasing company by Big Pharma.
- Provided patent preparation and prosecution, patent portfolio management and freedom to operate advice to a Fortune 500 company regarding foundational CRISPR-cas genome editing tools and techniques.
- Provide patent preparation and prosecution, patent portfolio management and freedom to operate advice to an international company developing new cell therapies based on CRISPR genome editing techniques.
- Provide comprehensive General IP counsel for a cutting-edge food ingredient innovation company in the highly dynamic plant-based foods industry. We provide regular counsel relating to IP transactions, the scope and strength of in-licensed patents, development of a comprehensive patent portfolio, and patent freedom-to-operate questions, supporting the company’s mission to make plant-based foods more flavorful and healthier. Our ongoing IP counsel recently supported a highly successful, industry record-setting Series B Financing round for the company.
- Assist physicians and academic researchers, as well as their renown university’s Ventures group, in the development, protection management and commercialization of IP to advance the reach and impact of groundbreaking treatments. This work encompasses a patent portfolio covering cord blood derived stem cells that are used for the treatment of autism, cerebral palsy and traumatic brain injury in children, as well as a key biologic used to treat Pompe disease.
- Assisted in formulating and implementing strategy at publicly traded bio-tech company to deal with influx of licensing demands through aggressive use of post grant proceeding. Results have substantially reduced client’s expected licensing costs resulting in increased profitability for multiple product lines.
- Successfully argued against the institution of an Inter Partes Review (IPR) Petition filed by a large international animal health company against a composition patent owned by an international OTC animal health pharmaceutical company client. Based on arguments made in defense of the client’s patent, the Patent Trial and Appeal Board (PTAB) declined to institute IPR of any challenged claims.
- Helped a company bring new animal health products to market by issuing freedom to operate opinions, drafting patient applications and working with executives to ensure entry into the marketplace and protection of intellectual property.
- Conducted intellectual property due diligence for the acquisition of a biomarker testing product company by a leading molecular diagnostic company.
- Negotiated a distribution/supply agreement between United States distributor and Korean manufacturing company covering distribution of immunochromatographic test kits for the qualitative detection of viruses affecting dogs or cats, including parvovirus, heartworm, and feline infectious peritonitis virus.
- Represent patent holder and prevented Inter Partes Review of orthopedic implant assemblies for joining bone segments.
- Prosecute and manage portfolio related to vaccine compatibility platform and timed vaccine delivery formulations platform.
- Regularly assist institution in evaluating early discoveries for potential patent filings and in consideration of international coverage value.
